5 trends tracked about this subject — the full history, oldest to newest below.
Bristol Myers Squibb reports successful Phase 2 results for its next-generation GPRC5D-directed CAR-T therapy targeting heavily treated myeloma patients.
Bristol Myers Squibb stock rises as its blood cancer cell therapy succeeds in a mid-stage trial.
The FDA has granted accelerated approval to Bristol Myers Squibb's Zenbexus, introducing a novel CELMoD drug class for multiple myeloma treatment.
9 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Sanofi's Sarclisa becomes the first cancer drug to receive FDA approval for delivery via a wearable on-body injector for multiple myeloma patients.